Effects of Montelukast sodium combined with Olopatadine in treatment of patients with chronic urticaria
Objective:To observe effects of Montelukast sodium combined with Olopatadine in treatment of patients with chronic urticaria.Methods:A prospective study was conducted on 70 patients with chronic urticaria admitted to this hospital from January 2022 to June 2023.According to the lottery method,they were divided into control group and observation group,35 cases in each group.The control group was treated with Olopatadine,while the observation group was treated with Montelukast sodium on the basis of that of the control group.The clinical symptom scores,the levels of inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),leukotriene E4(LTE4),eosinophil ratio]before and after the treatment,the disappearance time of clinical symptoms,the levels of Th1/Th2 cytokines[interferon-γ(IFN-γ)and interleukin-4(IL-4)],the clinical efficacy,and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the scores of pruritus,number of wheals and average diameter of wheals in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of hs-CRP,TNF-α,IL-6,LTE4 and the proportion of eosinophils in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The disappearance time of clinical symptoms such as itching,wheal and vascular edema in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the level of IL-4 in the observation group was lower than that in the control group,the level of IFN-γ was higher than that in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 91.43%(32/35),which was higher than 68.57%(24/35)in the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Olopatadine in the treatment of the patients with chronic urticaria can improve the total effective rate of treatment,improve the levels of Th1/Th2 cytokines,shorten the disappearance time of clinical symptoms,and reduce the clinical symptom scores and the inflammatory factor levels.Moreover,it is superior to single Olopatadine treatment.
NETL
NSTL
万方数据
维普
